CONTACT US
Home > Inhibitors/Agonists> > CL4H6
2256087-35-9-CL4H6 CL4H6

CL4H6

For research use only. Not for therapeutic Use.

  • CAT Number: I024872
  • CAS Number: 2256087-35-9
  • Molecular Formula: C59H113NO5
  • Molecular Weight: 916.555
  • Purity: 95%
Inquiry Now
Related Small Molecules: dUTP trisodium     Filorexant     Glutamate dehydrogenase    

CL4H6(CAT: I024872) is a Ph-sensitive cationic lipid. CL4H6 is a major component of lipid nanoparticles (LNPs) that can be used to target and deliver siRNA and induce effective gene-silencing responses. In vitro studies, CL4H6 was found to effectively target hepatocyte and endosomal escapes, safely and efficiently delivering myocardial associated transcription factor/serum response factor (MRTF/SRF) -B siRNA into human conjunctiva fibroblasts.


Catalog Number I024872
CAS Number 2256087-35-9
Synonyms

CL4H6; CL-4H6; CL 4H6;

Molecular Formula C59H113NO5
Purity 95%
Target Liposome
Solubility To be determined
Appearance Solid powder
Storage Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
IUPAC Name 7-(4-(dipropylamino)butyl)-7-hydroxytridecane-1,13-diyl dioleate
InChI InChI=1S/C59H113NO5/c1-5-9-11-13-15-17-19-21-23-25-27-29-31-33-39-47-57(61)64-55-45-37-35-41-49-59(63,51-43-44-54-60(52-7-3)53-8-4)50-42-36-38-46-56-65-58(62)48-40-34-32-30-28-26-24-22-20-18-16-14-12-10-6-2/h21-24,63H,5-20,25-56H2,1-4H3/b23-21-,24-22-
InChIKey ZFFZMGJMZGAGMF-SXAUZNKPSA-N
SMILES CCCN(CCC)CCCCC(CCCCCCOC(CCCCCCC/C=CCCCCCCCC)=O)(O)CCCCCCOC(CCCCCCC/C=CCCCCCCCC)=O
Reference

1: Sanghani A, Kafetzis KN, Sato Y, Elboraie S, Fajardo-Sanchez J, Harashima H, Tagalakis AD, Yu-Wai-Man C. Novel PEGylated Lipid Nanoparticles Have a High Encapsulation Efficiency and Effectively Deliver MRTF-B siRNA in Conjunctival Fibroblasts. Pharmaceutics. 2021 Mar 13;13(3):382. doi: 10.3390/pharmaceutics13030382. PMID: 33805660; PMCID: PMC7998417.
2: Sato Y, Nakamura T, Yamada Y, Harashima H. The nanomedicine rush: New strategies for unmet medical needs based on innovative nano DDS. J Control Release. 2021 Feb 10;330:305-316. doi: 10.1016/j.jconrel.2020.12.032. Epub 2020 Dec 20. PMID: 33358975.
3: Shobaki N, Sato Y, Suzuki Y, Okabe N, Harashima H. Manipulating the function of tumor-associated macrophages by siRNA-loaded lipid nanoparticles for cancer immunotherapy. J Control Release. 2020 Sep 10;325:235-248. doi: 10.1016/j.jconrel.2020.07.001. Epub 2020 Jul 8. PMID: 32649972.
4: Nakamura T, Yamada Y, Sato Y, Khalil IA, Harashima H. Innovative nanotechnologies for enhancing nucleic acids/gene therapy: Controlling intracellular trafficking to targeted biodistribution. Biomaterials. 2019 Oct;218:119329. doi: 10.1016/j.biomaterials.2019.119329. Epub 2019 Jul 4. PMID: 31306827.
5: Sato Y, Hashiba K, Sasaki K, Maeki M, Tokeshi M, Harashima H. Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo. J Control Release. 2019 Feb 10;295:140-152. doi: 10.1016/j.jconrel.2019.01.001. Epub 2019 Jan 2. PMID: 30610950.

Request a Quote